Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 76

Note*:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Global Markets Direct's, ‘Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016', provides in depth analysis on Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects

  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)

  • Identify the use of drugs for target identification and drug repurposing

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Review, H2 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) Overview 7
Therapeutics Development 8
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Stage of Development 8
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Therapy Area 9
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Indication 10
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Pipeline Products Glance 11
Late Stage Products 11
Early Stage Products 12
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Companies 13
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Products under Development by Universities/Institutes 15
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Therapeutics Assessment 17
Assessment by Monotherapy/Combination Products 17
Assessment by Mechanism of Action 18
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development 24
Aeterna Zentaris Inc. 24
Alize Pharma SAS 25
AstraZeneca Plc 26
Asubio Pharma Co., Ltd. 27
Motus Therapeutics Inc 28
Pfizer Inc. 29
RaQualia Pharma Inc. 30
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Drug Profiles 31
anamorelin hydrochloride - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
AZ-12861903 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
AZP-531 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
DLN-101 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
EXT-400 - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
HM-01 - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
HM-03 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
HM-04 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
macimorelin acetate - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
PF-05190457 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
relamorelin - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
RQ-00433412 - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Agonize Ghrelin Receptor for Obesity - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecule to Inverse Agonize Ghrelin Receptor for Obesity - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Dormant Projects 57
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Discontinued Products 60
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) - Featured News & Press Releases 62
Jul 18, 2016: Alize Pharma to present results from AZP-531 Phase II trial in Prader-Willi syndrome at two upcoming scientific conferences 62
Jun 01, 2016: Helsinn Group to Present at ASCO Pooled Follow up Efficacy Data Analysis From two Phase III Studies for Anamorelin in Cachectic Patients With Non-small Cell Lung Cancer 62
Apr 26, 2016: Alize Pharma reports positive results from its Phase II clinical trial of AZP-531 in Prader-Willi Syndrome 64
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis 65
Apr 04, 2016: Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia 65
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology 66
Jan 19, 2016: Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen 67
Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL 69
Nov 19, 2015: Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen for the evaluation of AGHD 69
Oct 29, 2015: Alize Pharma reports positive safety and efficacy results from a Phase Ib trial of AZP-531 in type 2 diabetes and provides an update on its overall clinical program 70
Sep 09, 2015: Additional data for anamorelin in ROMANA 1 and ROMANA 2 studies 71
Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD 72
May 26, 2015: Aeterna Zentaris' Confirmatory Phase 3 Study for Macrilen in AGHD Meets EMA's Study-Design Expectations 73
May 26, 2015: Alizé Pharma presents clinical results from the AZP-531 program at the American Diabetes Association 75th Scientific Sessions 73
May 20, 2015: Helsinn Group to present data on Anamorelin at 2015 ASCO 74
Appendix 75
Methodology 75
Coverage 75
Secondary Research 75
Primary Research 75
Expert Panel Validation 75
Contact Us 75
Disclaimer 76

List of Tables

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Number of Products under Development by Companies, H2 2016 13
Products under Development by Companies, H2 2016 14
Number of Products under Investigation by Universities/Institutes, H2 2016 15
Products under Investigation by Universities/Institutes, H2 2016 16
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Stage and Mechanism of Action, H2 2016 19
Number of Products by Stage and Route of Administration, H2 2016 21
Number of Products by Stage and Molecule Type, H2 2016 23
Pipeline by Aeterna Zentaris Inc., H2 2016 24
Pipeline by Alize Pharma SAS, H2 2016 25
Pipeline by AstraZeneca Plc, H2 2016 26
Pipeline by Asubio Pharma Co., Ltd., H2 2016 27
Pipeline by Motus Therapeutics Inc, H2 2016 28
Pipeline by Pfizer Inc., H2 2016 29
Pipeline by RaQualia Pharma Inc., H2 2016 30
Dormant Projects, H2 2016 57
Dormant Projects (Contd..1), H2 2016 58
Dormant Projects (Contd..2), H2 2016 59
Discontinued Products, H2 2016 60
Discontinued Products (Contd..1), H2 2016 61

List of Figures

Number of Products under Development for, H2 2016 8
Number of Products under Development by Therapy Area, H2 2016 9
Number of Products under Development by Top 10 Indication, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Early Stage Products, H2 2016 12
Assessment by Monotherapy/Combination Products, H2 2016 17
Number of Products by Mechanism of Actions, H2 2016 18
Number of Products by Stage and Mechanism of Actions, H2 2016 18
Number of Products by Routes of Administration, H2 2016 20
Number of Products by Stage and Routes of Administration, H2 2016 20
Number of Products by Molecule Types, H2 2016 22
Number of Products by Stage and Molecule Type, H2 2016 22
  • Global and United States Biobanking In-Depth Research Report 2017-2022
    Published: 20-Oct-2017        Price: US 3190 Onwards        Pages: 120
    The report is based on the market historical data from 2012 to 2016 and forecast the market trend from 2017 to 2022. This report focuses on the U.S. market and presents volume and value of market share by players, by regions, by product type, by consumers and also changes in prices. As an in-depth report, it covers all details inside analysis and opinions in Biobanking industry. Major Companies - Thermo Fisher Scientific Inc. (U.S.) - Tecan Group Ltd. ......
  • Global Biobanking Market Research Report 2017-2022 by Players, Regions, Product Types & Applications
    Published: 19-Oct-2017        Price: US 2380 Onwards        Pages: 124
    The global Biobanking market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. This report offers an overview of the market trends, drivers, and barriers with respect to the Biobanking market. It also provides a detailed overview of the market of different regions across United States, Europe, China, Japan, India, Southeast Asia and Others. The report categorizes Biobanking market by By P......
  • Global and Europe Biobanking Market - Analysis and Outlook to 2022
    Published: 19-Oct-2017        Price: US 2960 Onwards        Pages: 130
    This report presents a comprehensive overview of the Biobanking market in Europe, which shares the history data information from 2012 to 2016, and forecast from 2017 to 2022. This report provides a detailed analysis of the market, including its dynamics, structure, characteristics, main players, growth and demand drivers, etc. As a Detailed Analysis report, it covers all details inside analysis and opinion in Biobanking industry. This report focuses Global and Europ......
  • 2017-2022 Global and Japan Biobanking Market Analysis Report
    Published: 19-Oct-2017        Price: US 3085 Onwards        Pages: 120
    The global Biobanking market is valued at XX million USD in 2016 and is expected to reach XX million USD by the end of 2017, growing at a CAGR of XX% between 2016 and 2022. Japan plays an important role in global market, with market size of xx million USD in 2016 and will be xx million USD in 2017, with a CAGR of xx%. This report, with focus on top players in the global and Japan, studies the Biobanking market's development status and future trend in the global and ......
  • Global Biobanking Detailed Analysis Report 2017-2022
    Published: 19-Oct-2017        Price: US 3250 Onwards        Pages: 121
    This report mainly introduces volume and value market share by players, by regions, by product type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Biobanking industry. This report splits Biobanking market By Product and Service, By Sample, which covers the history data information from 2012 to 2016 and forecast from 2017 to 2022. This report focuses Global market, it covers detai......
  • China Contract Research Organization (CRO) Industry Report, 2017-2021
    Published: 18-Oct-2017        Price: US 2700 Onwards        Pages: 110
    Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the development of new drugs assisted by CRO firms in recent years, stimulating the progression of global CRO industry which had a market size of USD31.7 billion in 2016. There are more than 1,100 CRO companies around the world, led by Quintiles IMS, Covance, in Ventiv Health, Charles River, Parex......
  • Global Digital PCR (dPCR) Sales Market Report 2017
    Published: 18-Oct-2017        Price: US 4000 Onwards        Pages: 111
    In this report, the global Digital PCR (dPCR) market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Digital PCR (dPCR) for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japa......
  • Global Somatostatin Sales Market Report 2017
    Published: 18-Oct-2017        Price: US 4000 Onwards        Pages: 114
    In this report, the global Somatostatin market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K MT), revenue (Million USD), market share and growth rate of Somatostatin for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan - Sout......
  • China Gene Synthesis Market by Manufacturers, Regions (Province), Type and Application, Forecast to 2022
    Published: 18-Oct-2017        Price: US 4480 Onwards        Pages: 117
    Gene synthesis refers to chemically synthesizing a strand of DNA base-by-base. Unlike DNA replication that occurs in cells or by Polymerase Chain Reaction (PCR), gene synthesis does not require a template strand. Rather, gene synthesis involves the step-wise addition of nucleotides to a single-stranded molecule, which then serves as a template for creation of a complementary strand. Gene synthesis is the fundamental technology upon which the field of synthetic biology has been built. ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs